Showing 17,701 - 17,720 results of 29,654 for search '(( 50 ((n decrease) OR (a decrease)) ) OR ( 5 ((nm decrease) OR (nn decrease)) ))', query time: 0.95s Refine Results
  1. 17701

    Image_2_RNA 2’-O-Methyltransferase Fibrillarin Facilitates Virus Entry Into Macrophages Through Inhibiting Type I Interferon Response.tif by Panpan Li (484033)

    Published 2022
    “…Once FBL is down-regulated, the decreased Nm modifications of RNA in macrophages may act as “non-self” RNA and be recognized by RNA sensor interferon induced with helicase C domain 1 (MDA5), leading to innate immune activation by inducing the expression of IFN-I and ISGs. …”
  2. 17702
  3. 17703
  4. 17704

    The synergistic effect of RAL and HAFi in the protein expression of pro-HB-EGF in mouse skin and in human skin atrophy. by Laurent Barnes (358736)

    Published 2013
    “…<p><b>A.</b> Western blot analysis on the protein extracts of vehicle-, RAL-, HAFi- or RAL- and HAFi-treated SKH1 hairless mice for active HB-EGF (∼15 kDa) (a), pro-HB-EGF (∼25 kDa) (b) and erbB1 (∼170 kDa) (c) and loading control α-tubulin (50 kDa) (d). …”
  5. 17705

    Downregulation of COP9 signalosome subunits differentially affects the CSN complex and target protein stability-3 by Andreas Peth (85734)

    Published 2011
    “…The upper panel shows the phosphorylation of c-Jun by autoradiography demonstrating a decrease of c-Jun phosphorylation by more than 50% as estimated by densitometry. …”
  6. 17706

    Synthesis, Structure, and Transannular π−π Interaction of Three- and Four-Layered [3.3]Paracyclophanes by Masahiko Shibahara (1709875)

    Published 2008
    “…The effect of an increase in the layers becomes significant, and the changes in the longest wavelength λ<sub>max</sub> values from two to three and three to four are ca. 60 and 50 nm, respectively. By comparison of the stereoisomeric four-layered [3.3]PCPs <b>4</b> (meso) and <b>5</b> (racemic), the helical arrangement of the trimethylene bridges of <b>5</b> shows a more efficient transannular π-electronic interaction. …”
  7. 17707

    Synthesis, Structure, and Transannular π−π Interaction of Three- and Four-Layered [3.3]Paracyclophanes by Masahiko Shibahara (1709875)

    Published 2008
    “…The effect of an increase in the layers becomes significant, and the changes in the longest wavelength λ<sub>max</sub> values from two to three and three to four are ca. 60 and 50 nm, respectively. By comparison of the stereoisomeric four-layered [3.3]PCPs <b>4</b> (meso) and <b>5</b> (racemic), the helical arrangement of the trimethylene bridges of <b>5</b> shows a more efficient transannular π-electronic interaction. …”
  8. 17708

    Synthesis, Structure, and Transannular π−π Interaction of Three- and Four-Layered [3.3]Paracyclophanes by Masahiko Shibahara (1709875)

    Published 2008
    “…The effect of an increase in the layers becomes significant, and the changes in the longest wavelength λ<sub>max</sub> values from two to three and three to four are ca. 60 and 50 nm, respectively. By comparison of the stereoisomeric four-layered [3.3]PCPs <b>4</b> (meso) and <b>5</b> (racemic), the helical arrangement of the trimethylene bridges of <b>5</b> shows a more efficient transannular π-electronic interaction. …”
  9. 17709

    Synthesis, Structure, and Transannular π−π Interaction of Three- and Four-Layered [3.3]Paracyclophanes by Masahiko Shibahara (1709875)

    Published 2008
    “…The effect of an increase in the layers becomes significant, and the changes in the longest wavelength λ<sub>max</sub> values from two to three and three to four are ca. 60 and 50 nm, respectively. By comparison of the stereoisomeric four-layered [3.3]PCPs <b>4</b> (meso) and <b>5</b> (racemic), the helical arrangement of the trimethylene bridges of <b>5</b> shows a more efficient transannular π-electronic interaction. …”
  10. 17710

    Synthesis, Structure, and Transannular π−π Interaction of Three- and Four-Layered [3.3]Paracyclophanes by Masahiko Shibahara (1709875)

    Published 2008
    “…The effect of an increase in the layers becomes significant, and the changes in the longest wavelength λ<sub>max</sub> values from two to three and three to four are ca. 60 and 50 nm, respectively. By comparison of the stereoisomeric four-layered [3.3]PCPs <b>4</b> (meso) and <b>5</b> (racemic), the helical arrangement of the trimethylene bridges of <b>5</b> shows a more efficient transannular π-electronic interaction. …”
  11. 17711

    Glucagon-like peptide 1 (GLP-1) secretion in response to oral glucose tolerance test (oGTT). by Christine Bernsmeier (237984)

    Published 2014
    “…<p><b>(A)</b> GLP-1 secretion in response to oGTT is significantly decreased in patients vs. controls (p<0.001). …”
  12. 17712

    TOR is required for endocycle progression to activate ecdysone biosynthesis. by Yuya Ohhara (3697570)

    Published 2017
    “…<p><b>(A)</b> Expression of TOR<sup>DN</sup> in the PG causes arrest in DNA content increase at the 3rd instar larval stage. …”
  13. 17713
  14. 17714

    Clinical and virological profiles of EVN<sub>Term</sub> challenged vaccinated and naïve ponies. by Jodi K. Craigo (421284)

    Published 2013
    “…<p>The profiles depicted in A–I display the clinical and virological outcomes observed in EIAV<sub>D9</sub> vaccinated animals (<b>A–E</b>), and EIAV naïve animals (<b>F–I</b>) upon challenge with 10<sup>3</sup> TCID<sub>50</sub> EV<sub>NTerm</sub> chimeric proviral strain. …”
  15. 17715
  16. 17716
  17. 17717
  18. 17718
  19. 17719
  20. 17720

    DataSheet_1_Patient-Reported Outcomes-Guided Adaptive Radiation Therapy for Head and Neck Cancer.docx by Sarah Weppler (10931013)

    Published 2021
    “…Dose-PRO relationships were strongest between delivered pharyngeal constrictor Dmean and patient-reported dysphagia, with MDADI composite scores (mean ± SD) of 25.7 ± 18.9 for patients with Dmean <50 Gy vs. 32.4 ± 17.1 with Dmean ≥50 Gy. Based on logistic regression models, during-treatment dose corrections back to planned values may confer ≥5% decrease in the absolute risk of self-reported physical dysphagia symptoms ≥1 year post-treatment in 1.2% of patients, with a ≥5% decrease in relative risk in 23.3% of patients.…”